Anne Clem Whitaker

Insider · Director · ICLR

Anne Clem Whitaker files insider transactions with the SEC as a director of Icon (ICLR). We hold 1 disclosed purchase or sale filed since 4 December 2013, 1 of them in the last 90 days.

Files forICLR
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure12 August 2026

Positions held

8 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 10 August 2026 — 11 August 2026Director · Icon (ICLR)7 Form 4 lines · source: SEC Form 4
Filed 8 November 2021 — 16 May 2023Director · Orasure Technologies (OSUR)4 Form 4 lines · source: SEC Form 4
Filed 1 November 2020 — 10 January 2022Director · Caladrius Biosciences (CLBS)3 Form 4 lines · source: SEC Form 4
Filed 6 November 2020 — 6 November 2020Director · Mallinckrodt (MNKKQ)1 Form 4 line · source: SEC Form 4
Filed 2 December 2013 — 5 November 2020Director · Cree (CREE)22 Form 4 lines · source: SEC Form 4
Filed 16 May 2018 — 13 May 2020Director · Mallinckrodt (MNK)4 Form 4 lines · source: SEC Form 4
Filed 13 May 2015 — 5 December 2016EVP, Company Group Chairman · Valeant Pharmaceuticals International (VRX)8 Form 4 lines · source: SEC Form 4
Filed 2 September 2014 — 2 March 2015President and CEO · Synta Pharmaceuticals (SNTA)4 Form 4 lines · source: SEC Form 4

Everything they disclosed

53 entries, newest first — one per disclosure report, one per Form 4 line

exercised options over 1,732 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 10 August 2026 · filed 12 August 2026
▼ sold on the open market 88 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 96 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 590 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 67 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
exercised options over 1,732 shares of Icon (a derivative holding)SEC Form 412 August 2026Restricted Share Units · traded 10 August 2026 · filed 12 August 2026
was granted 1,324 shares of Icon (a derivative holding)SEC Form 412 August 2026Restricted Share Units · traded 10 August 2026 · filed 12 August 2026
had shares withheld for tax on 4,400 shares of Orasure TechnologiesSEC Form 417 May 2023Common Stock · traded 15 May 2023 · filed 17 May 2023
had shares withheld for tax on 2,323 shares of Orasure TechnologiesSEC Form 417 May 2023Common Stock · traded 16 May 2023 · filed 17 May 2023
was granted 20,000 shares of Orasure TechnologiesSEC Form 418 May 2022Common Stock · traded 16 May 2022 · filed 18 May 2022
was granted 65,430 shares of Caladrius BiosciencesSEC Form 412 January 2022Common Stock · traded 10 January 2022 · filed 12 January 2022
was granted 10,563 shares of Orasure TechnologiesSEC Form 410 November 2021Common Stock · traded 8 November 2021 · filed 10 November 2021
was granted 37,735 shares of Caladrius BiosciencesSEC Form 412 January 2021Common Stock · traded 11 January 2021 · filed 12 January 2021
▼ sold on the open market 21,087 shares of MallinckrodtSEC Form 410 November 2020Ordinary Shares · traded 6 November 2020 · filed 10 November 2020
exercised options over 4,000 shares of Cree (a derivative holding)SEC Form 46 November 2020NONQUALIFIED STOCK OPTION (RIGHT TO BUY) · traded 5 November 2020 · filed 6 November 2020
exercised options over 4,000 shares of CreeSEC Form 46 November 2020COMMON STOCK · traded 5 November 2020 · filed 6 November 2020
▼ sold on the open market 4,000 shares of CreeSEC Form 46 November 2020COMMON STOCK · traded 5 November 2020 · filed 6 November 2020
▼ sold on the open market 25,248 shares of CreeSEC Form 46 November 2020COMMON STOCK · traded 5 November 2020 · filed 6 November 2020
was granted 79,470 shares of Caladrius BiosciencesSEC Form 43 November 2020Common Stock · traded 1 November 2020 · filed 3 November 2020
was granted 2,652 shares of CreeSEC Form 43 September 2020COMMON STOCK · traded 1 September 2020 · filed 3 September 2020
had shares withheld for tax on 8,729 shares of MallinckrodtSEC Form 415 May 2020Ordinary Shares · traded 13 May 2020 · filed 15 May 2020
was granted 3,217 shares of CreeSEC Form 44 September 2019COMMON STOCK · traded 1 September 2019 · filed 4 September 2019
had shares withheld for tax on 8,527 shares of MallinckrodtSEC Form 417 May 2019Ordinary Shares · traded 15 May 2019 · filed 17 May 2019
was granted 19,396 shares of MallinckrodtSEC Form 417 May 2019Ordinary Shares · traded 15 May 2019 · filed 17 May 2019
was granted 3,566 shares of CreeSEC Form 45 September 2018COMMON STOCK · traded 1 September 2018 · filed 5 September 2018
was granted 18,947 shares of MallinckrodtSEC Form 418 May 2018Ordinary Shares · traded 16 May 2018 · filed 18 May 2018
was granted 7,033 shares of CreeSEC Form 46 September 2017COMMON STOCK · traded 1 September 2017 · filed 6 September 2017
had shares withheld for tax on 834 shares of Valeant Pharmaceuticals InternationalSEC Form 420 December 2016Common Stock, no par value · traded 2 August 2016 · filed 20 December 2016
had shares withheld for tax on 6,012 shares of Valeant Pharmaceuticals InternationalSEC Form 420 December 2016Common Stock, no par value · traded 5 December 2016 · filed 20 December 2016
had shares withheld for tax on 6,505 shares of Valeant Pharmaceuticals InternationalSEC Form 47 December 2016Common Stock, no par value · traded 5 December 2016 · filed 7 December 2016
was granted 6,429 shares of CreeSEC Form 46 September 2016COMMON STOCK · traded 1 September 2016 · filed 6 September 2016
was granted 37,935 shares of Valeant Pharmaceuticals InternationalSEC Form 416 May 2016Common Stock, no par value · traded 12 May 2016 · filed 16 May 2016
▼ sold on the open market 623 shares of CreeSEC Form 418 February 2016COMMON STOCK · traded 16 February 2016 · filed 18 February 2016
was granted 6,674 shares of CreeSEC Form 43 September 2015COMMON STOCK · traded 1 September 2015 · filed 3 September 2015
▼ sold on the open market 1,994 shares of CreeSEC Form 43 September 2015COMMON STOCK · traded 3 September 2015 · filed 3 September 2015
was granted 7,500 shares of Valeant Pharmaceuticals InternationalSEC Form 422 July 2015Restricted Share Units · traded 20 July 2015 · filed 22 July 2015
was granted 112,455 shares of Valeant Pharmaceuticals InternationalSEC Form 424 June 2015Restricted Share Units · traded 13 May 2015 · filed 24 June 2015
▲ bought on the open market 5,000 shares of Valeant Pharmaceuticals InternationalSEC Form 427 May 2015Common Stock, no par value · traded 26 May 2015 · filed 27 May 2015
▲ bought on the open market 2,500 shares of Valeant Pharmaceuticals InternationalSEC Form 427 May 2015Common Stock, no par value · traded 26 May 2015 · filed 27 May 2015
was granted 100,000 shares of Synta Pharmaceuticals (a derivative holding)SEC Form 44 March 2015Employee Stock Option (Right to Buy) · traded 2 March 2015 · filed 4 March 2015
was granted 687 shares of CreeSEC Form 423 January 2015COMMON STOCK · traded 22 October 2014 · filed 23 January 2015
was granted 553 shares of CreeSEC Form 423 January 2015COMMON STOCK · traded 21 January 2015 · filed 23 January 2015
▼ sold on the open market 624 shares of CreeSEC Form 423 January 2015COMMON STOCK · traded 22 January 2015 · filed 23 January 2015
was granted 4,244 shares of CreeSEC Form 424 October 2014COMMON STOCK · traded 2 September 2014 · filed 24 October 2014
was granted 500,000 shares of Synta PharmaceuticalsSEC Form 44 September 2014Common Stock · traded 2 September 2014 · filed 4 September 2014
was granted 500,000 shares of Synta Pharmaceuticals (a derivative holding)SEC Form 44 September 2014Employee Stock Option (Right to Buy) · traded 2 September 2014 · filed 4 September 2014
was granted 250,000 shares of Synta Pharmaceuticals (a derivative holding)SEC Form 44 September 2014Employee Stock Option (Right to Buy) · traded 2 September 2014 · filed 4 September 2014
was granted 4,244 shares of CreeSEC Form 43 September 2014COMMON STOCK · traded 2 September 2014 · filed 3 September 2014
was granted 278 shares of CreeSEC Form 415 August 2014COMMON STOCK · traded 13 August 2014 · filed 15 August 2014
was granted 245 shares of CreeSEC Form 425 April 2014COMMON STOCK · traded 23 April 2014 · filed 25 April 2014
acquired or disposed of, other 185 shares of CreeSEC Form 424 January 2014COMMON STOCK · traded 22 January 2014 · filed 24 January 2014
was granted 4,000 shares of Cree (a derivative holding)SEC Form 44 December 2013NONQUALIFIED STOCK OPTION (RIGHT TO BUY) · traded 2 December 2013 · filed 4 December 2013
was granted 4,000 shares of CreeSEC Form 44 December 2013COMMON STOCK · traded 2 December 2013 · filed 4 December 2013

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.